Bayer’s AskBio unit has reported the first clinical data for its congestive heart failure gene therapy, showing preliminary signs of efficacy with no serious adverse event
A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular
Novo Nordisk’s obesity therapy Wegovy has cut the risk of death by 19% in the SELECT trial, mirroring the benefits of the drug in cardiovascular outcomes in people who are
US intelligence services advised the authors of the BIOSECURE Act that that WuXi AppTec shared confidential data on US customers with the Chinese government, according to